RMD 1201
Alternative Names: RMD-1201Latest Information Update: 01 Dec 2023
At a glance
- Originator Remedium Bio
- Class Diabetes gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Type 1 diabetes mellitus
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 01 Dec 2023 RMD 1201 is still in preclinical trials for Type 1 diabetes mellitus in USA (IV)
- 14 Jul 2023 Discontinued - Preclinical for Type 2 diabetes mellitus in USA (IV), prior to July 2023 (Remedium Bio pipeline, July 2023)
- 10 Jan 2022 Remedium Bio and University of Massachusetts enter into a Sponsored Research Agreement to complete preclinical efficacy studies in Type 1 and Type 2 diabetes pipeline candidates